Analyst Price Target is $43.20
▲ +45.80% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Akero Therapeutics in the last 3 months. The average price target is $43.20, with a high forecast of $56.00 and a low forecast of $30.00. The average price target represents a 45.80% upside from the last price of $29.63.
Current Consensus is
Moderate Buy
The current consensus among 7 polled investment analysts is to moderate buy stock in Akero Therapeutics. This rating has held steady since April 2024, when it changed from a Buy consensus rating.
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Read More